Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eton Pharmaceuticals, Inc.ETON · Entity 4598 | Director | March 12, 2020 | March 16, 2020 |
| HARROW, INC.HROW · Entity 4740 | Director · CHIEF EXECUTIVE OFFICER | May 14, 2026 | May 15, 2026 |
| Ideal Power Inc.IPWR · Entity 6940 | Director | March 03, 2017 | March 06, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eton Pharmaceuticals, Inc.
Report date March 12, 2020 · Filed March 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.58 · Expires 2030-03-11 | Direct | 27,400 |
Reported balance
After 2020-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-12 · Grant · Acquired 27,400 · Balance 27,400 F1: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on March 12, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on March 12, 2021.
HARROW, INC.
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,996,130 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Purchase · Acquired 10,000 · Balance 2,996,130 F1: The price reported in Column 4 is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $30.18 to $30.34, inclusive. The reporting person undertakes to provide to Harrow, Inc., any security holder of Harrow, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $30.18 to $30.34, inclusive. The reporting person undertakes to provide to Harrow, Inc., any security holder of Harrow, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Ideal Power Inc.
Report date March 03, 2017 · Filed March 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 33,698 |
Reported balance
After 2017-03-03 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2017-03-03 · Purchase · Acquired 7,800 · Balance 33,698 F1: The reported securities are included within the securities purchased by the reporting person for $2.535 per share of common stock together with a warrant to purchase one share of common stock. F2: The securities are owned by Beadore Trust dated March 20, 2015. The reporting person has voting and investment control over the securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 29,063 |
Reported balance
Holding disclosure · report date 2017-03-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 29,063 F2: The securities are owned by Beadore Trust dated March 20, 2015. The reporting person has voting and investment control over the securities. |
| Common Stock WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.41 · Expires 2020-03-03 | IndirectSee Footnote | 7,800 |
Reported balance
After 2017-03-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-03 · Purchase · Acquired 7,800 · Balance 7,800 F1: The reported securities are included within the securities purchased by the reporting person for $2.535 per share of common stock together with a warrant to purchase one share of common stock. F2: The securities are owned by Beadore Trust dated March 20, 2015. The reporting person has voting and investment control over the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are included within the securities purchased by the reporting person for $2.535 per share of common stock together with a warrant to purchase one share of common stock.
F2: The securities are owned by Beadore Trust dated March 20, 2015. The reporting person has voting and investment control over the securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2018 Filed Nov 16, 2018 00:06 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 10,000 | $6.00 | $60,000.00 |
DisclosureSEC source: 0001209191-18-058821 · doc4.xml · nonDerivative · entry 1 BAUM MARK L · CIK 0001274282 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,000 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:30 UTC | HARROW, INC. IMMY · Entity 4740 | GrantOption - Right to Buy · Derivative | 150,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001493152-18-000185 · form4.xml · derivative · entry 1 BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: Represents stock options granted under the Issuer's 2017 Stock Incentive and Awards Plan. The stock options vest in equal quarterly installments over a three year period. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 21:31 UTC | Ideal Power Inc. IPWR · Entity 6940 | PurchaseCommon Stock Warrants · Derivative | 7,800 | $2.54 Strike: $2.41 | $19,773.00 |
DisclosureSEC source: 0001144204-17-012979 · v461161_4.xml · derivative · entry 3 BAUM MARK L · CIK 0001274282 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2020-03-03 F1 · price: The reported securities are included within the securities purchased by the reporting person for $2.535 per share of common stock together with a warrant to purchase one share of common stock. F2 · ownership.nature: The securities are owned by Beadore Trust dated March 20, 2015. The reporting person has voting and investment control over the securities. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 21:31 UTC | Ideal Power Inc. IPWR · Entity 6940 | PurchaseCommon Stock | 7,800 | $2.54 | $19,773.00 |
DisclosureSEC source: 0001144204-17-012979 · v461161_4.xml · nonDerivative · entry 1 BAUM MARK L · CIK 0001274282 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 33,698 F1 · price: The reported securities are included within the securities purchased by the reporting person for $2.535 per share of common stock together with a warrant to purchase one share of common stock. F2 · ownership.nature: The securities are owned by Beadore Trust dated March 20, 2015. The reporting person has voting and investment control over the securities. Read SEC document |
| February 01, 2017 Filed Feb 4, 2017 02:16 UTC | HARROW, INC. IMMY · Entity 4740 | GrantOption - Right to Buy · Derivative | 160,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001493152-17-001107 · form4.xml · derivative · entry 1 BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2027-02-01 F1 · derivative.exercise_date: Represents stock options granted under the Issuer's 2007 Stock Incentive and Awards Plan. The stock options vest in equal quarterly installments over a three year period. Read SEC document |
| January 03, 2017 Filed Jan 20, 2017 13:15 UTC | Ideal Power Inc. IPWR · Entity 6940 | GrantOption to Purchase Stock · Derivative | 27,875 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001144204-17-002987 · v457134_form4.xml · derivative · entry 1 BAUM MARK L · CIK 0001274282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,875 Underlying: Common Stock · 27,875 shares Expires 2027-01-03 F1 · security: The option was issued from the Ideal Power Inc. (formerly known as Ideal Power Converters, Inc.) Amended & Restated 2013 Equity Incentive Plan, as in existence on the date of grant. F2 · security: The grant represents an annual automatic grant of options to each independent member of the Issuer's Board of Directors, which was inadvertently not timely reported. F3 · derivative.exercise_date: The right to purchase the common stock vests as follows: the right to purchase 6,968 shares of common stock vests on March 31, 2017; the right to purchase 6,969 shares of common stock vests on June 30, 2017; the right to purchase 6,969 shares of common stock vests on September 30, 2017; and the right to purchase 6,969 shares vests on December 31, 2017. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 21:02 UTC | HARROW, INC. IMMY · Entity 4740 | Exercise / conversionRestricted Stock Unit · Derivative | 200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-16-016102 · form4.xml · derivative · entry 5 BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes. F2 · derivative.exercise_date: On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes. F2 · derivative.expiration_date: On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 21:02 UTC | HARROW, INC. IMMY · Entity 4740 | PurchasePurchase Warrant · Derivative | 156,000 | $0.13 Strike: $1.79 | $19,500.00 |
DisclosureSEC source: 0001493152-16-016102 · form4.xml · derivative · entry 4 BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,000 Underlying: Common Stock · 156,000 shares Expires 2019-12-23 F1 · kind: On December 19, 2016, the Beadore Trust dated March 20, 2015, through which Mr. Baum has voting and investment control over the securities, entered into a definitive agreement to acquire 156,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors. F3 · price: The value of the Purchase Warrant included in each Unit is $0.125. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 21:02 UTC | HARROW, INC. IMMY · Entity 4740 | Disposition to issuerCommon Stock | 83,709 | $1.72 | $143,979.48 |
DisclosureSEC source: 0001493152-16-016102 · form4.xml · nonDerivative · entry 3 BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,126 F2 · security: On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 21:02 UTC | HARROW, INC. IMMY · Entity 4740 | Exercise / conversionCommon Stock | 200,000 | $1.72 | $344,000.00 |
DisclosureSEC source: 0001493152-16-016102 · form4.xml · nonDerivative · entry 2 BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 21:02 UTC | HARROW, INC. IMMY · Entity 4740 | PurchaseCommon Stock | 156,000 | $1.79 | $279,240.00 |
DisclosureSEC source: 0001493152-16-016102 · form4.xml · nonDerivative · entry 1 BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,835 F1 · kind: On December 19, 2016, the Beadore Trust dated March 20, 2015, through which Mr. Baum has voting and investment control over the securities, entered into a definitive agreement to acquire 156,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors. Read SEC document |
| July 31, 2015 Filed Jul 24, 2025 01:10 UTC | HARROW, INC. HROW · Entity 4740 | Exercise / conversionStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0001641172-25-020751 · ownership.xml · derivative · entry 3 BAUM MARK L · CIK 0001274282 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2025-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents stock options granted to Mr. Baum on July 31, 2015, and amended on June 4, 2020, under the Issuer's 2007 Stock Incentive and Awards Plan, as amended. The stock option vested upon achievement and maintenance of certain Harrow common stock-price-based performance targets. The Company withheld a total of 313,338 shares from issuance to Mr. Baum for: (i) 127,346 shares withheld as consideration for the cashless exercise of the option; and (ii) an additional 185,992 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes. F1 · derivative.exercise_date: Represents stock options granted to Mr. Baum on July 31, 2015, and amended on June 4, 2020, under the Issuer's 2007 Stock Incentive and Awards Plan, as amended. The stock option vested upon achievement and maintenance of certain Harrow common stock-price-based performance targets. The Company withheld a total of 313,338 shares from issuance to Mr. Baum for: (i) 127,346 shares withheld as consideration for the cashless exercise of the option; and (ii) an additional 185,992 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.